. 2016 Feb 1;31(2):61–68. doi: 10.1097/YIC.0000000000000110
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.http://creativecommons.org/licenses/by-nc-nd/4.0/.
Table 3.
Adverse events during the double-blind treatment period (safety population)
